Cargando…
Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors
Although the clinical efficacies of third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) such as osimertinib in the treatment of non-small cell lung cancer (NSCLC) with EGFR-activating mutations are promising, drug-acquired resistance inevitably occurs whether t...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442612/ https://www.ncbi.nlm.nih.gov/pubmed/37609474 http://dx.doi.org/10.1016/j.pccm.2022.10.001 |